|
|
Vaccine Detail
|
PR1 Leukemia Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: PR1 Leukemia Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007074
- Type: Peptide vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- TMEM37
gene engineering:
- Preparation: The peptide vaccine is co-administered with GM-CSF (Qazilbash et al., 2017).
- Description: This is for Leukemia Cancer (NCT00004918).A cancer vaccine containing PR1, a 9 amino-acid human leukocyte antigen (HLA)-A2 restricted peptide derived from proteinase 3, with potential immunotherapeutic activity. Vaccination with PR1 leukemia peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing proteinase 3, resulting in tumor cell lysis. Often overexpressed in leukemic cells, proteinase 3 is a serine proteinase that activates progelatinase A and is involved in angiogenesis and metastasis (NCIT_C2235). PR1 is a 9 amino acid-long peptide derived from the myeloid proteins proteinase 3 (P3) and neutrophil elastase (NE) (Qazilbash et al., 2017).
|
| Host Response |
|
|
| References |
NCIT_C2235: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2235]
NCT00004918: [https://clinicaltrials.gov/show/NCT00004918/]
Qazilbash et al., 2017: Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJ. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017; 31(3); 697-704. [PubMed: 27654852].
|
|
